1Student, Department of Pharmacy, LBYP College Of Pharmacy, Pathri, India 431 111
2Assistant Professor, Department of Pharmacy, LBYP College Of Pharmacy, Pathri, India 431 111
3Principal, Department of Pharmacy, LBYP College Of Pharmacy, Pathri, India 431 111
Liposomes play a pivotal role in drug delivery, particularly in the context of proteins and peptides. This abstract explores their application as carriers for these bioactive compounds, highlighting the challenges and advancements in the field. The encapsulation of proteins and peptides within liposomal structures enhances their stability, prolongs circulation time, and facilitates targeted delivery. Various methods of liposome preparation and surface modifications are discussed, addressing issues like immunogenicity and release kinetics. The integration of nanotechnology with protein and peptide drug delivery holds promising prospects for improving therapeutic outcomes and reducing side effects. This abstract provides a concise overview of the current state and future directions in this dynamic and evolving field.
1. Grubber, S.M. Liposome Biophysics Therapeutics, Marcel Dekker: New York, 1987.
2. Bangham, A.D. Liposomes in Biological Systems, John Wiley and Sons: Chichester, 1980.
3. Jayakrishnan, A.; Latha, M.S. Controlled and Novel Drug Delivery, B.S. Pub: New Delhi, 1997.
4. Gregoriadis, G. Methods Enzymol., 1976, 44, 278.
5. T. Hamada and K. Yoshikawa, Materials, 2012, 5, 2292-2305.
6. F. de Meyer and B. Smit, Proc. Natl. Acad. Sci., 2009, 106, 3654.
7. T. Subramani and H. Ganapathyswamy, J. Food Sci. Technol., 2020, 57, 3545-3555.
8. T. Subramani and H. Ganapathyswamy, J. Food Sci. Technol., 2020, 57, 3545-3555.
9. Allen TM, Hansen C, Martin F, Redemann C, YauYoung A. 1991. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29±36.
10. Beauchamp C, Daddona PE, Menapace DP. 1984. Properties of a novel PEG derivative of calf adenosine deaminase. Adv Exp Med Biol 165
11. Torchilin VP. 1994. Immunoliposomes and PEGylated immunoliposomes: possible use of targeted delivery of imaging agents. Immunomethods 4: 244±258.
12. Risbo J, Jorgensen K, Sperotto MM, Mouritsen OG.1997. Phase behavior and permeability properties of phospholipid bilayers containing a short-chain phospholipidpermeability enhancer. Biochim Biophys Acta 1329:85±96.
13. Corvera E, Mouritsen OG, Singer MA, ZuckermannMJ. 1992. The permeability and the effect of acylchain length for phospholipid bilayers containing cholesterol: Theory and experiment. Biochim Biophys Acta 1107:261±270.
14. Dunnick . J. K; Rookie, J.D ; Aragon, S ; kriss , J. P. Cancer, Res, 1976, 36, 2385-2389.
15. Posted, G. Liposomes in Biological system, John Wiley and sons, 1980.
16. Amaranth Sharma*, Uma S. Sharma ; Liposomes in drug delivery: progress and limitations, Department of Experimental Therapeutics, Roswell Park Cancer Institute, and Department of Pharmaceutics, SUNY at Buffalo, Buffalo, NY, USA.Gluck, R.; Mischelar, R.; Brantschen, S.; Just, M.; Althaus, B.; Cryz, S. J. J. Clin. Invest., 1992, 90, 2491.
17. Moghimi SM (2002) Chemical camouflage of nanospheres with a poorly reactive surface: Towards development of stealth and targetspecific nanocarriers. Biochim Biophys Acta 1590:131–139.
18. Mc Cayley , J.A.; Flory’s Book.; Mc Comb. T.G. Biochim. Biophys. Acta, 1992, 30,112.
19. Satyanarayan U, Chakrapani U, Biochemistry, 3rd Ed., Books and allied (p) Ltd., Kolkata, 2008; 43-44.
20. Banga A.K. and Chein Y.W, Systemic delivery of therapeutic peptides and proteins, Int. J. Pharmaceutics, 1988; 48: 15?50
21. Meyer et al. Transdermal delivery of human insulin to albino rabbits using electrical current. Am. J. Med. Sci., 1989; 297: 321?325.
22. Tahami. Alkhaled and Singh J., Recent patent on drug delivery and formulation, 2007; 1:65?71.
23. Lin SY and Yang JC, Effect of _-cyclodextrin on the in vitro permeation rate and in vivo rectal absorption of acetaminophen hydrogel preparations. Pharm. Acta Helv., 1990; 65:262-268.
24. Arima H et al. Use of water soluble _-cyclodextrin derivatives as carriers of anti inflammatory drug bi phenylyl acetic acid in rectal delivery. Yakugaku Zasshi. 1992; 112:65-72.
25. Brouard A et al. Rectal administration of carbamazepine gel. Clin. Pharm. 1990; 9:13–14.
26. Maloney CM et al. The rectal administration of MS contin: clinical implications of use in end stage therapy cancer. Am. J. Hosp Care. 1989; 6(4): 34-35.
27. Batul N et al. Pharmacokinetics of two novel rectal controlled release morphine formulations. J. Pain Symptom Manage. 1992; 7(7): 400-405.
28. Warren DE. Practical use of rectal medications in palliative care. J. Pain Symptom Manage. 1996; 11(6): 378-387.
29. Sarwar, G. The protein digestibility-corrected amino acid score method overestimates quality of proteins containing antinutritional factors and of poorly digestible proteins supplemented with limiting amino acids in rats. Journal of Nutrition 1997; 127: 758-764.
30. Tikkanen, M.J., Wahala, K., Ojala, S., Vihma, V., and Adlecrerutz, H. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proclamations of the National Academy of Science 1998; 95: P3106-P3110.
31. Higuchi T. Mechanism of sustained-action medication. J Pharm Sci 1963; 52: 1145–1149.
32. Kwok WY, Kiparisider C, Yuet P, Harris TJ and Goosen MFA. Mathematical modelling of protein diffusion in microcapsules: a comparison with experimental results. Can J Chem Eng 1990; 68.
33. Okhamafe AO and Goosen MFA. Modulation of membrane permeability. In: Kuhtrelber WM, Lanza RP and Chick WL(Eds.). Cell Encapsulation Technology and Therapeutics. Birkhäuser Boston Inc, 1999; 53–62.
34. G. P. Li, Z. G. Liu, B. Liao and N. S. Zhong, ?Induction of Th1-Type Immune Response by Chitosan Nanoparti-cles Containing Plasmid DNA Encoding House Dust Mite Allergen Der p 2 for Oral Vaccination in Mice,? Cellular & Molecular Immunology, 2009; 6(1): 45-50. doi:10.1038/cmi.2009.6
35. I. S. Kim, S. K. Lee, Y. M. Park, Y. B. Lee and S. C. Shin, ?Physicochemical Characterization of Poly(L-lactic acid) and Poly(D,L-lactide-co-glycolide) Nanoparticles with Polyethylenimine as Gene Delivery Carrier,? Interna-tional Journal of Pharmaceutics, 2005; 298(1): 255-262. doi:10.1016/j.ijpharm.2005.04.017
36. ANGELINI, “EPAXAL®—Vaccine for Active Immuni- sation against Hepatitis A,”2011. http://www.angelini.it/public/schedepharma/epaxal.htm
37. J. L. Italia, A. Sharp, K. C. Carter, P. Warn and M. N. V. R. Kumar, ?Peroral Amphotericin B Polymer Nanoparti-cles Lead to Comparable or Superior in Vivo Antifungal Activity to That of Intravenous Ambisome® or Fungizone™,? PLoS One, 2011; 6(10): 8. doi:10.1371/journal.pone.0025744
38. R. Rupp, S. L. Rosenthal and L. R. Stanberry, ?VivaGel (SPL7013 Gel): A Candidate Dendrimer—Microbicide for the Prevention of HIV and HSV Infection,? International Journal of Nanomedicine, 2007; 2(4): 561-566.
39. H. Sarin, ?Recent Progress towards Development of Ef-fective Systemic Chemotherapy for the Treatment of Ma-lignant Brain Tumors,? Journal of Translational Medi-cine, 2009; 7: 77. doi:10.1186/1479-5876-7-77
40. National Diabetes Data Group, Diabetes in America: Diabetes Data Compiled 1984. Bethesda Md. NIH. 85, 1985; 146X.
41. Calceti, P. et al. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci., 2004; 22: 315–323
42. Basu, A. et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjugate Chem. 2006; 17: 618–630
43. Wang, J. et al. Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Release, 2003; 26: 369–380
44. Kipnes, M. et al. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care, 2003; 26: 421–42
Pratik Dhone, Priyanka Shelke, Gajanan Sanap, Liposomes, Protein And Peptide Drug Delivery Systems, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 1, 90-100. https://doi.org/10.5281/zenodo.10466154